• SIGN IN
  • GET HELP
  •  

    Webinar Details


    Event Type

    Live Online

    Date

    Monday, September 23, 2019

    Time

    2:00 PM - 4:00 PM ET

    Location

    PharmCon Webinar Studio (freeCE.com)

    Credits

    2 Contact Hour(s)

    Target Audience

    Pharmacist, Pharmacy Technician, Nurse

    Cost

    $45.00

    • Overview

      Patients with diabetes are also much more likely to suffer from cardiovascular disease than those without diabetes. In fact, cardiovascular disease is the leading cause of death associated with diabetes – certainly a medical double jeopardy. The American Diabetes Association’s (ADA) recently published the 2017 Standards of Medical Care in Diabetes and included new recommendations on treating both diabetes and cardiovascular disease. Pharmacists are often the medical professional that patients reach out to for guidance and explanation on new pharmaco-therapy and individualized treatment. This program will review the ADA’s latest update to the Standards of Medical Care in Diabetes, review recent outcomes trials of antihyperglycemic therapies in patients with type 2 diabetes (T2D) and outline evidence based treatment strategies to mitigate the risk of cardiovascular disease in patients with T2D. 

      Handouts

      Slide Document 18265L01_6pp.pdf
      Slide Document 18265L01_2pp.pdf





      Financial Support By

      PharmCon
    • Pharmacist

      Summarize the ADA and AACE guidelines with respect to efficacy and safety particularly when analyzing cardiovascular and renal outcomes
      Recognize the drug therapies and show evidence of benefit in improving blood sugars and decreasing risk of cardiovascular and renal events
      Identify guidelines that are recommended by the ADA and AACE for CV risk reduction and the others in this class

      Pharmacy Technician

      Review how different treatment options work to lower blood sugar levels in patients with diabetes
      Recognize the effects of diabetes agents on glycosylated hemoglobin levels (A1c)
      List some common safety concerns about different agents used to treat type 2 diabetes

      Nurse

      Summarize the ADA and AACE guidelines with respect to efficacy and safety particularly when analyzing cardiovascular and renal outcomes
      Recognize the drug therapies and show evidence of benefit in improving blood sugars and decreasing risk of cardiovascular and renal events
      Identify guidelines that are recommended by the ADA and AACE for CV risk reduction and the others in this class
    • Repeat Presentation

      This presentation was last given on 9/23/2019 2:00 PM

      Future Airings

      There are no future airings of this activity scheduled at this time.

    • Activity Type

      Knowledge

      CE Broker

      20-644281

      Universal Activity Number

      Pharmacist 0798-0000-18-265-L01-P

      Pharmacy Technician 0798-0000-18-265-L01-T

      Nurse 0798-0000-18-265-L01-N

      ACPE PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

      In order to obtain a Statement of Credit, attendees must answer poll questions and complete a program evaluation. Attendees may immediately print their Statement of Credit or leave them stored on the website.

    • Faculty

      Tamara  Goldberg, PharmD, BCPS
      Associate Professor of Pharmacy Practice, Arnold & Marie Schwartz College of Pharmacy and Health Sciences Long Island University

    HARDWARE REQUIREMENTS
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
     


    SOFTWARE REQUIREMENTS
    Microsoft Edge
    Internet Explorer 8.0 or higher
    Google Chrome
    Safari
    Firefox 3.0.3 or higher


    NETWORK REQUIREMENTS
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
     
     

    This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).




    Computer sharing is NOT permitted due to accreditation guidelines on activity monitoring. Credit is earned by one user per device.